preliminari oper result introduc sale
growth oper margin guidanc weve chanc
speak manag offer follow key take-away
preliminari guidanc seem conserv especi
top-lin growth outlook commit invest behind
capac expans new product launch improv qualiti
drive sustain longer term growth well posit
growth tailwind multipl new launch
manag confid near-term timelin conclud
intern investig report full result believ
lrp long-rang plan updat sep analyst meet could
mirror intact revenu growth outlook softer margin
net-net believ well posit continu
posit growth momentum wise invest
longer term opportun increas price target
base updat ev/ebitda dcf p/e/g analysi
guid sale growth report ex-fx
adjust oper margin former seem
somewhat conserv rel growth
appropri start point year view busi
could see growth improv renal acut nutrit due easier
comp driven new launch side could see
somewhat slower growth medic deliveri tougher comp
iv therapi tough comp compound
gener competit inject anesthesia advanc
surgeri tougher comp margin line believ outlook
reason rel margin
manag commit invest capac expans new
launch point cap margin upsid bax track record
suggest compani may abl better
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud one-tim item adjust
compani data secur llc estim reuter
continu previou page
commit invest support import new opportun compani
oper margin guidanc lrp analyst meet believ
manag good job articul reason behind increment spend much
base event play invest behind renal busi
invest like acceler follow kidney initi announc juli propos
initi effect target doubl percentag patient home dialysi next year
opportun could signific materi also invest behind
theranova proprietari dialyz us launch manag sound confid get
new tech add-on payment theranova help adopt factor pressur near-term
margin includ invest improv manufactur qualiti price impact iv therapi
contract sing past year
bax portfolio appear well posit growth beyond medic deliveri
compani launch new pump platform broaden reach pump
market make offer competit addit multi-year idn contract iv solut
provid greater stabil visibl iv therapi busi expect
new product like myxredlin insulin addit molecul clari provid new revenu
opportun beyond renal manag clearli excit theranova
potenti increas share dialyz market estim us dialyz market
theranova price premium current dialyz
updat intern investig manag seem confid investig conclud
come week compani expect posit report full result
end file financi restat necessari stem result investig
bottom-lin expect investig overhang uncertainti remov near-term
lrp updat expect see revenu growth intact lower oper
margin plan host analyst day sep updat lrp outlook time
base sale oper margin guidanc expect top-lin growth outlook
compound-annual-growth-rate remain intact howev note previou oper margin
target could somewhat lower base expect said see still
see potenti off-set lower tax rate previous set
price target
price target base equal weight ev/ebtida dcf p/e/g risk
thesi includ uncertainti intern investig unexpect competit headwind could
slow restructur effort signific delay new launch
believ deliv guidanc acceler sale growth margin expans ep
growth
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
